QRxPharma shares plummet 80%
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
Shares in QRxPharma (QRX) have plummeted 80% in early trade after the Food and Drug Administration in the US failed to approve its pain drug, Moxduo.
At 11.20am (AEDT) QRxPharma shares were 79.29% lower at 14.5 cents, against a benchmark index lift of 0.67%. In earlier trade, QRxPharma shares hit as low as 10.5 cents.
The FDA Anesthetic and Analgesic Drug Products Advisory Committee voted against approval of Moxduo, an immediate release dual opioid for the treatment of moderate to severe acute pain. The advisory committee found QRxPharma did not provide sufficient evidence to warrant approval of the drug at this time.
"We are obviously disappointed in the outcome of today's meeting, but remain confident in the advantages of Moxduo compared to morphine and oxycodone," QRxPharma chief executive officer John Holaday said.
"This is a necessary therapy for patients with moderate to severe acute pain.
"We are committed to bringing to market safer therapies for pain, such as Moxduo, and preventing opioid abuse."
Call 1300 880 160
Start a chat
Schedule a call
